Open AccessPharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
Author(s) -
Patricia MuñozVillegas,
Alejandra SánchezRíos,
Mayra G Quiñonez-Alvarado,
Oscar OlveraMontaño,
Juan D Quintana-Hau,
Leopoldo Martín Baiza-Durán
Publication year - 2021
Publication title -
journal of experimental pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1179-1454
DOI - 10.2147/jep.s308388
Subject(s) - bevacizumab , pharmacokinetics , cmax , medicine , adverse effect , biosimilar , ranibizumab , pharmacology , vascular endothelial growth factor , ophthalmology , vegf receptors , chemotherapy
PRO-169 is a biosimilar candidate to bevacizumab (BEV), a monoclonal antibody (mAb) that inhibits vascular endothelial growth factor-A (VEGF-A) developed for intravitreal use. The current study demonstrates the intraocular pharmacokinetics (PK) of PRO-169 and its safety using New Zealand white (NZW) rabbits.